​oncofocus
ASCO 2018 annual meeting is over and, like last year's conference, several key findings were presented. We have been actively tracking developments in the CAR-T space and had published a pipeline landscape report before the conference. If you have not already read it, you can do so by downloading it HERE.

We are now completing the series – CAR-Ts in ASCO – with a report summarizing key updates concerning clinical stage CAR-Ts at ASCO 2018. 

The data presented covered major aspects of the CAR-Ts’ use case in the Oncology treatment landscape, for example –

• Positive efficacy and safety data bringing two more CAR-Ts closer to filing/approval by 2019
• Potential prognostic factors to distinguish patients who can attain long-termclinical benefits
• Genetic biomarkers that could be helpful in identifying patients prone to neurotoxicity​​
• Optimal sequenceof the CAR-Ts in the present treatment regimen

​You can download our Post-conference report by fillling the form. Please do let us know your thoughts/suggestions on our work. We would be happy to receive your feedback.

Happy Reading!